title: CD4+ CD25+ lymphocyte and dendritic cell mobilization with intermediate doses of recombinant human granulocyte colony-stimulating factor in healthy donors.
abstract: We prospectively conducted a quantitative and phenotypic analysis of T, B, natural killer (NK), NKT, type 1 and 2 dendritic cells (DC), and regulatory T cells, before and after mobilization with intermediate doses of granulocyte colony-stimulating factor (G-CSF) (16 microg/kg per day). Between November, 2003, and December, 2004, we collected stem cells from 25 HLA identical sibling donors for allogeneic hematopoietic stem cell transplantation. Before mobilization and 3 h after the fourth and fifth doses of G-CSF, blood samples were taken for blood counts and flow cytometry. The median number of regulatory T cells before and after G-CSF was statistically different (69 +/- 41 x 10(6)/L versus 161 +/- 159 x 10(6)/L, p < 0.01). We observed a 1.7-fold increase in NK and NKT cells (p < 0.009 and p < 0.02, respectively). DC were mobilized with a 11.5-fold increase in type 2 (p < 0.004) and a 8.5-fold increase in type 1 DC (p < 0.003). The patients received a mean of: 2.2 x 10(7)/kg +/- 1.4 x 10(7)/kg of NK cells, 0.95 x 10(7)/kg +/- 0.81 x 107/kg of NKT cells, 0.43 x 107/kg +/- 0.53 x 10(7)/kg of type 1 DC, 0.3 v 10(7)/kg +/- 0.45 x 10(7)/kg of type 2 DC and 1.4 x 10(7)/kg +/- 1.2 x 10(7)/kg of regulatory T cells. Using intermediate doses of G-CSF, we have demonstrated the mobilization of different lymphocyte subsets, in particular regulatory T cells and DC, which can be expanded later and used in the treatment of cancer and autoimmune diseases.
authors.affiliation: Hematology Department, Stem Cell Transplant Program, Unidad Médica de Alta Especialiad Antonio Fraga Mouret Centro Médico La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico. velaj12x@prodigy.net.mx
authors.forename: J
authors.initials: J
authors.lastname: Vela-Ojeda
authors.forename: M A García-Ruiz
authors.initials: MA
authors.lastname: Esparza
authors.forename: E
authors.initials: E
authors.lastname: Reyes-Maldonado
authors.forename: L
authors.initials: L
authors.lastname: Jiménez-Zamudio
authors.forename: E
authors.initials: E
authors.lastname: García-Latorre
authors.forename: M
authors.initials: M
authors.lastname: Moreno-Lafont
authors.forename: I
authors.initials: I
authors.lastname: Estrada-García
authors.forename: H
authors.initials: H
authors.lastname: Mayani
authors.forename: L
authors.initials: L
authors.lastname: Montiel-Cervantes
authors.forename: F
authors.initials: F
authors.lastname: Tripp-Villanueva
authors.forename: M
authors.initials: M
authors.lastname: Ayala-Sánchez
authors.forename: L D
authors.initials: LD
authors.lastname: García-León
authors.forename: J R
authors.initials: JR
authors.lastname: Borbolla-Escoboza
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D001781:Blood Component Removal / Q000379:methods; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D017690:Cell Transplantation / Q000379:methods*; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D006801:Humans; D019520:Living Donors; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000032:analysis*; D011994:Recombinant Proteins; D035781:Siblings; D013234:Stem Cells / Q000166:cytology*
chemical_list: D015703:Antigens, CD; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor